Uncovering the hidden socioeconomic impact of juvenile idiopathic arthritis and paving the way for other rare childhood diseases: an international, cross-disciplinary, patient-centered approach (PAVE Consortium)


Por: Marshall DA, Gerber B, Currie GR, Anton-Lopez J, De Somer L, Dey M, Egert T, Egert Y, Henan L, Klotsche J, Martinez-Mifsut L, Minden K, Normand C, Porte D, Saurenmann RK, Swart JF, Uziel Y, Wilson J, Wouters C, Ziv A and Benseler SM

Publicada: 9 ago 2024 Ahead of Print: 9 ago 2024
Resumen:
BackgroundJuvenile idiopathic arthritis (JIA) refers to a heterogeneous group of rheumatic conditions in children. Novel drugs have greatly improved disease outcomes; however, outcomes are impacted by limited awareness of the importance of early diagnosis and adequate treatment, and by differences in access across health systems. As a result, patients with JIA continue to be at risk for short- and long-term morbidity, as well as impacts on virtually all aspects of life of the child and family. Main bodyLiterature on the socioeconomic burden of JIA is largely focused on healthcare costs, and the impact of JIA on patients, families, and communities is not well understood. High quality evidence on the impact of JIA is needed to ensure that patients are receiving necessary support, timely diagnostics, and adequate treatment, and to inform decision making and resource allocation. This commentary introduces the European Joint Programme on Rare Diseases: Producing an Arthritis Value Framework with Economic Evidence: Paving the Way for Rare Childhood Diseases (PAVE) project, which will co-develop a patient-informed value framework to measure the impact of JIA on individuals and on society. With a patient-centered approach, fundamental to PAVE is the involvement of three patient advocacy organizations from Canada, Israel, and Europe, as active research partners co-designing all project phases and ensuring robust patient and family engagement. The framework will build on the findings of projects from six countries: Canada, Germany, Switzerland, Spain, Israel, and Belgium, exploring costs, outcomes (health, well-being), and unmet needs (uveitis, mental health, equity). ConclusionThis unique international collaboration will combine evidence on costs (from family to societal), outcomes (clinical, patient and family outcomes), and unmet needs, to co-design and build a framework with patients and families to capture the full impact of JIA. The framework will support the development of high-quality evidence, encompassing economic and clinical considerations, unmet needs, and patient perspectives, to inform equitable resource allocation, health system planning, and quality of care better aligned with the needs of children with JIA, their families, and communities. Knowledge gained from this novel approach may pave the way forward to be applied more broadly to other rare childhood diseases.

Filiaciones:
Marshall DA:
 Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

 Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada

 McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada

 O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada

Gerber B:
 Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Currie GR:
 Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

 Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada

 Department of Pediatrics, University of Calgary, Calgary, AB, Canada

 University of Calgary, Health Research Innovation Centre, Room 3C56, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada

Anton-Lopez J:
 Study Group of Diseases Due to Immune Dysfunction in Pediatrics (GEMDIP), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain

 Department of Surgery, Surgical Specialties and Pediatrics, Universitat de Barcelona, Barcelona, Spain

 Department of Pediatric Rheumatology, Hospital Sant Joan de Déu, ERN RITA and ReCONNET Center, Esplugues de Llobregat, Barcelona, Spain

De Somer L:
 Department of Microbiology and Immunology, KU Leuven - University of Leuven, Leuven, Belgium

 Pediatric Rheumatology Leuven University Hospital, Leuven, Belgium

Dey M:
 School of Health Science, Institute of Public Health, ZHAW Zurich University of Applied Sciences, Winterthur, Switzerland

Egert T:
 INBAR - Israeli Arthritis Foundation, Ramat Gan, Israel

Egert Y:
 INBAR - Israeli Arthritis Foundation, Ramat Gan, Israel

Henan L:
 Meir Medical Center, Department of Pediatrics, Pediatric Rheumatology Unit, Kfar Saba, Israel

Klotsche J:
 German Rheumatism Research Centre, Berlin, Germany

Martinez-Mifsut L:
 Hospital Sant Joan de Déu, Patient Experience Area, Esplugues de Llobregat, Spain

Minden K:
 German Rheumatism Research Centre, Berlin, Germany

 Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany

Normand C:
 European Network for Children With Arthritis and Autoinflammatory Diseases (ENCA), Gradignan, France

Porte D:
 Cassie and Friends Society, Vancouver, Canada

Saurenmann RK:
 Department of Pediatrics, Cantonal Hospital Winterthur, Brauerstr, Winterthur, Switzerland

Swart JF:
 Department of Pediatric Immunology, Wilhelmina Children's Hospital / University Medical Center, Utrecht, The Netherlands

 Faculty of Medicine, Utrecht University, Utrecht, The Netherlands

Uziel Y:
 School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

 Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel

Wilson J:
 Cassie and Friends Society, Vancouver, Canada

Wouters C:
 Department of Microbiology and Immunology, KU Leuven - University of Leuven, Leuven, Belgium

 Pediatric Rheumatology Leuven University Hospital, Leuven, Belgium

Ziv A:
 Meir Medical Center, Department of Pediatrics, Pediatric Rheumatology Unit, Kfar Saba, Israel

Benseler SM:
 Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada

 Department of Pediatrics, University of Calgary, Calgary, AB, Canada

 Alberta Health Services, Calgary, AB, Canada
ISSN: 15460096





Pediatric Rheumatology
Editorial
BMC, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Estados Unidos America
Tipo de documento: Letter
Volumen: 22 Número: 1
Páginas: 74-74
WOS Id: 001287498600001
ID de PubMed: 39118107
imagen Green Published, gold

MÉTRICAS